ARO AAT

Drug Profile

ARO AAT

Alternative Names: ARO-AAT

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arrowhead Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha 1-antitrypsin deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alpha 1-antitrypsin deficiency

Most Recent Events

  • 29 Jun 2018 Efficacy, adverse events and pharmacodynamics data from a phase I trial in Alpha 1-antitrypsin deficiency released by Arrowhead Pharmaceuticals
  • 27 Jun 2018 The EMA's Committee for Orphan Medicinal Products grants a positive opinion for Orphan drug status to ARO AAT for the treatment of Alpha-1 antitrypsin deficiency
  • 18 Jun 2018 Arrowhead Pharmaceuticals completes enrolment in phase I trial for Alpha 1-antitrypsin deficiency (In Volunteers) in New Zealand (NCT03362242)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top